Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of Treatment with Perindopril, Amlodipine, and Indapamide SR

Clinical Drug Investigation

Volumn 34, Issue 10, 2014, Pages 701-708

  Páll, Dénes ^a   Szántó, Ildikó ^a   Szabó, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; PERINDOPRIL; AMLODIPINE, PERINDOPRIL DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ADULT; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE THERAPY; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84919327219     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0223-0     Document Type: Article

References (30)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
2. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.
3. Managing hypertension in childhood and adulthood: professional and organisational guidelines. Position statement and recommendations of the Hungarian Society of Hypertension, 9th ed. [in Hungarian]. Hypertonia Nephrologia. 2009;13(S2):81–168.
4. Rurik I, Sandholzer H. Obesity among Hungarian elderly. Acta Alimentaria. 2009;38:361–7.
5. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
6. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279–86.
7. Thoenes M, Neuberger HR, Volpe M, et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24(5):336–44.
8. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31.
9. Kjeldsen SE, Messerli FH, Chiang CE, et al. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28(10):1685–97.
10. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31:251–8.
11. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.
12. Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
13. Barna I, Keszei A, Dunai A. Evaluation of Meditech ABPM-04 ambulatory blood pressure measuring device according to the British Hypertension Society protocol. Blood Press Monit. 1998;3(6):363–8.
14. O’Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ. 2000;320(7242):1128–34.
15. Volpe M, de la Sierra A, Ammentorp B, et al. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther. 2014;31(5):561–74.
16. Ram CV. Fixed-dose triple-combination treatments in the management of hypertension. Manag Care. 2013;22(12):45–55.
17. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–45.
18. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone-system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.
19. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61(2):131–42.
20. Páll D, Juhász M, Paragh G, et al. Evidence-based combination treatment of hypertension [in Hungarian]. Gen Pract Training Rev. 2009;14(4):219–22.
21. Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the action in diabetes and vascular disease: preterax and diamicron controlled evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259–64.
22. Omboni S, Fogari R, Palatini P, et al. Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study. Hypertension. 1998;32(3):424–9.
23. Rosendorff C. Why are we still using hydrochlorothiazide? J Clin Hypertens (Greenwich). 2011;13(12):867–9.
24. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869–78.
25. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124(2):128–35.
26. Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26.
27. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907–13.
28. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.
29. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.
30. Thomas F, Pannier B, Safar ME. Impact of country of birth on arterial function in subjects living in France. J Am Soc Hypertens. 2012;6(6):405–13.